Solventum reported $8.31B of revenue over the trailing twelve months, −0.93% on the year before. 11 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $8.31B (to Q2 2026). Net income: $1.43B, trailing twelve months to Q2 2026. Free cash flow: −$118M, trailing twelve months to Q2 2026. Operating margin: 25%, trailing twelve months to Q2 2026.

SOLVSolventum

Healthcare

$87.38+17% 1Y

$87.38

$62.4952 weeks$92.40

SOLV as reported

Solventum reported $8.31B of revenue over the trailing twelve months, −0.93% on the year before. 11 reported series are charted on this page, each one as filed.

$8.31B

Revenue, trailing twelve months · to Q2 2026 · −0.93% against the twelve months before

Net income: $1.43B
Net income · +277% year on year · trailing twelve months to Q2 2026
Free cash flow: −$118M
Free cash flow · −180% year on year · trailing twelve months to Q2 2026
Operating margin: 25%
Operating margin · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for SOLV, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$8.31B	−0.93%	Q2 2026
Net income	$1.43B	+277%	Q2 2026
EPS	$8.17	+276%	Q2 2026
Gross margin	55%	n/a	Q2 2026
Operating margin	25%	n/a	Q2 2026
Net margin	17%	n/a	Q2 2026
ROE	30%	n/a	Q2 2026
ROA	11%	n/a	Q2 2026
ROIC	18%	n/a	Q2 2026
Free cash flow	−$118M	−180%	Q2 2026
P/E	10.7	n/a	today

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.